RDIF and Samruk-Kazyna Ink Cooperation Memorandum to Battle COVID-19
Posted on 07/20/2020
The Russian Direct Investment Fund and Samruk-Kazyna have signed a memorandum of cooperation to counteract coronavirus COVID-19 pandemic. Kazakhstan has already received 9,500 packages of Avifavir, the world’s first registered favipiravir-based drug against coronavirus.
According to the press release, “Under the memorandum, RDIF has already delivered the first batches of coronavirus drug Avifavir to the Republic of Kazakhstan. This is the first Russian drug approved to treat coronavirus infection and the world’s first registered favipiravir-based drug against COVID-19 with clinically proven efficacy. Avifavir blocks the reproduction mechanisms of coronavirus, relieving symptoms and halving the treatment period compared to standard therapy. The efficacy has been proven in clinical trials held in 35 medical centers across Russia involving 330 patients with confirmed COVID-19.
RDIF and Samruk-Kazyna have also agreed to cooperate in clinical trials, procurement and production of a vaccine against coronavirus. In accordance with the memorandum, the parties will consider the possibility of obtaining the necessary certification in Kazakhstan for the first Russian vaccine against COVID-19 developed by the Gamaleya National Research Institute of Epidemiology and Microbiology to be supplied to the country or produced locally.”
